

PRODUCT INFORMATION




AZ 33

Item No. 25444

CAS Registry No.: 1370290-34-8
Formal Name: 2-[[4-[4-[[3-[(2-methyl-6-benzothiazolyl)amino]-3-oxopropyl]amino]-4-oxobutyl]phenyl]methyl]-propanedioic acid

MF: C₂₅H₂₇N₃O₆S
FW: 497.6
Purity: ≥98%
UV/Vis.: λ_{max}: 223, 280 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AZ 33 is supplied as a crystalline solid. A stock solution may be made by dissolving the AZ 33 in the solvent of choice. AZ 33 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of AZ 33 in ethanol is approximately 2 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of AZ 33 can be prepared by directly dissolving the crystalline solid in aqueous buffers. AZ 33 is slightly soluble in PBS, pH 7.2. We do not recommend storing the aqueous solution for more than one day.

Description

AZ 33 is an inhibitor of lactate dehydrogenase A (LDHA; $K_d = 0.093 \mu\text{M}$; $IC_{50} = 0.5 \mu\text{M}$).¹ It is selective for LDHA over LDHB in an NADH competition assay using recombinant enzymes (IC_{50} s = 0.54 and 3.6 μM , respectively).² AZ 33 is cell-impermeable and lacks cytotoxicity against HeLa cervical cancer cells ($IC_{50} = >500 \mu\text{M}$).

References

1. Ward, R.A., Brassington, C., Breeze, A.L., *et al.* Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. *J. Med Chem.* **55(7)**, 3285-3306 (2012).
2. Granchi, C., Calvaresi, E.C., Tuccinardi, T., *et al.* Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. *Org. Biomol. Chem.* **11(38)**, 6588-6596 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/15/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM